查詢結果分析
來源資料
相關文獻
- 轉移性乳癌的化學治療
- 一位乳癌患者接受乳房切除與化學治療的護理經驗
- 乳癌的化學治療
- 轉移性乳癌化學治療之新利器--微脂體包覆化學藥物Liposomal Doxorubicin
- 乳癌病人用藥依從性及相關因素之研究
- Fatigue and Related Factors in Women with Breast Cancer Receiving Chemotherapy
- Factors Related to Quality of Life in Breast Cancer Patients Receiving Chemotherapy
- MVP (Mitomycin-C, Vinblastine, Cisplatin) Salvage Chemotherapy for Relapsed and Refractory Metastatic Breast Cancer
- High-Dose Chemotherapy with Autologous Peripheral Blood Stem-Cell Support for High-Risk Primary Breast Cancer
- 植入皮下注射器作乳癌病人化學治療的經驗--100例報告
頁籤選單縮合
題 名 | MVP (Mitomycin-C, Vinblastine, Cisplatin) Salvage Chemotherapy for Relapsed and Refractory Metastatic Breast Cancer=復發及頑抗性轉移乳癌之MVP(Mitomycin-C, Vinblastine, Cisplatin)救援性化學治療 |
---|---|
作 者 | 許駿; 葉坤輝; 洪瑞隆; 楊志新; 林敏哲; 陳耀昌; 鄭安理; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 96:3 1997.03[民86.03] |
頁 次 | 頁185-188 |
分類號 | 416.226 |
關鍵詞 | 乳癌; 化學治療; Breast cancer; Chemotherapy; Mitomycin-C; Vinblastine; Cisplatin; |
語 文 | 英文(English) |
英文摘要 | Salvage chemotherapy for relapsed and refractory metastatic breast cancer is a challenging issue for oncologists. At our institution, the combination of mitomycin-C, vinblastine and cisplatin (MVP) is used for treatment. The records of 19 consecutive patients with refractory metastatic breast cancer treated with MVP between April 1992 and October 1995 were reviewed. The regimen consisted of mitomycin-C 6 mg/m ��, vinblastine mg/m �� and cisplatin 60 mg/m ��,repeated every 3 to 4 weeks. The median age of patients was 49 years (range, 35-71 yr). All patients had clinically measurable or evaluable disease and a Karnofsky's performance status greater than or equal to 50%. The median number of prior chemotherapy regimens was two (range, 1-4). Eighteen (94.7%) patients had previously received an anthracycline/ anthracenedione-containing regimen, and seven (36.9%) had progression of disease during these therapies. Sixteen patients had two or more sites of metastasis and 17 patients had visceral disease. The median duration of follow-up was 26 months. A mean of 3.5 courses (range,1-7) was administered. Oen patient was lost to follow-up after one course of treatm ent. Of the remaining 18 patients, two complete and five partial responses were observed, for a total response rate of 37% (range, 17-61%,95% CI).One of the partial responders had disease progression during anthracycline treatment. Treatment-related toxicities were relatively well toerated. There were no treatment-related deaths. The median duration of response was 3 months (range, 2-11 mo). The median overall survival was 7 months (range, 1-32 mo). Our data suggest that the MVP regimen is an effective palliative treatment for patients with refractory metastatic breast cancer. |
本系統中英文摘要資訊取自各篇刊載內容。